Immutep Limited (IMM.AX) Stock Analysis & Winston Score

Immutep is an Australian biotechnology company that develops drugs to help the immune system fight cancer and autoimmune diseases. Its main focus is a protein called LAG-3, which plays a role in controlling immune responses, and the company's lead drug candidate is eftilagimod alpha (efti), which is being tested in clinical trials for cancers like breast cancer and lung cancer. Immutep is one of the few companies in the world focused specifically on LAG-3 as a treatment platform. The company does not yet sell any approved products, so it earns money mainly through licensing deals and partnerships with larger pharmaceutical companies, including a long-standing collaboration with GSK. It operates primarily out of Australia and Germany, with clinical trials running across multiple countries. The key growth driver is getting efti through late-stage clinical trials and winning regulatory approval, but the main risk is that clinical-stage biotech companies frequently run out of cash before reaching that milestone, and Immutep is no exception given its deeply negative margins.